Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 3-DIMENSIONAL PHARMACEUTICALS (DDDP) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (115)	12/6/2002 12:11:13 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 146

Dr. William Claypool, 51................................................................ 2002 2005 Dr. William Claypool joined us as a director in January 2002. Dr. Claypool has served as the CEO of Phoenix Data Systems, Inc. since June 2001. Dr. Claypool also served as CEO of the GI Company from January 2001 to June 2001. From 1991 to December 2000, Dr. Claypool held a number of key management positions of increasing responsibility with SmithKline Beecham Pharmaceuticals. Most notably, he was Senior Vice President and Worldwide Medical Director, Clinical Research and Development from November 1998 to December 2000. Prior to his tenure with SmithKline Beecham, Dr. Claypool was employed with G.D. Searle & Co. in Clinical Research. Prior to beginning his career in industry, Dr. Claypool held academic positions at the University of Pennsylvania School of Medicine, the University of Pittsburgh School of Medicine, and the University of Illinois at Chicago College of Medicine. He has been an active member of many organizations including the American Thoracic Society, the American College of Chest Physicians, the American Federation for Clinical Research, the Chicago Thoracic Society, and the American Physiology Society. He has been published in many highly regarded pharmaceutical publications as well. Dr. Claypool earned a B.S. from the University of Notre Dame and an M.D. from the University of Connecticut School of Medicine. He did his residency and fellowship at the Hospital of the University of Pennsylvania. Mr. Joshua Ruch, 52..................................................................... 1997 2005 Mr. Joshua Ruch has been a director with us since March 1997. Mr. Ruch is the Chairman and Chief Executive Officer of Rho Capital Partners, Inc., an international investment management firm which he co-founded in 1981. Prior to founding Rho Capital Partners, Inc., Mr. Ruch was employed in investment banking at Salomon Brothers and Bache Halsey Stuart, Inc. Mr. Ruch received a B.S. degree in electrical engineering from the Israel Institute of Technology (Technion) and an MBA from the Harvard Business School. Mr. Ruch also serves on the Board of Directors of Diacrin, Inc., a public company, as well as several private companies in the technology sector. Dr. F. Raymond Salemme, 57.............................................................. 1993 2005 Dr. F. Raymond Salemme founded the Company in 1993, and has served as a director since February 1993. Dr. Salemme currently serves as President and Chief Scientific Officer, positions he has held since June 1998 and June 1996, respectively. Dr. Salemme was Chairman of the Company from June 1996 to June 1998, and served as President and Chief Executive Officer from February 1993 to June 1996. Dr. Salemme is co-inventor on 14 US patents covering our DirectedDiversity(R) chemi-informatics process control technology and our ThermoFluor assay technology. Prior to founding our company, Dr. Salemme established drug discovery groups specializing in structure-based drug design, biophysics, and computational chemistry at Sterling Winthrop Pharmaceuticals and DuPont Merck Pharmaceuticals, Inc. Dr. Salemme also worked in Central Research and Development at DuPont, where he led research in protein X-ray crystallography and engineering, developed computational methods for crystallography and drug design, and conducted large-scale computational simulations of proteins and polymer systems. In 1983, Dr. Salemme founded the Protein Engineering Division of Genex Corporation, among the first companies to use X-ray crystallography and molecular modeling for genetically engineering proteins. From 1973 to 1983, Dr. Salemme was Professor of Biochemistry at the University of Arizona and published extensively in the areas of molecular structures of redox proteins, the theory of biological electron transfer and protein architecture. Dr. Salemme received a B.A. in Molecular Biophysics from Yale University (with exceptional distinction) and a Ph.D. in Chemistry from the University of California, San Diego, where his Ph.D. thesis solved one of the first high-resolution 3-D protein structures by X-ray crystallography. In addition to duties at 3DP, Dr. Salemme serves on several corporate scientific and academic advisory boards, as well as federal advisory committees on advanced technology and biotechnology, including the National Institute of Science and Technology (NIST) Visiting Committee on Advanced Technology and advisory committees for the National Institutes of Health.